Previous studies demonstrated that FLT3‐ITD, TP53, RUNX1, ASXL1 aberrations, and KMT2A rearrangements are associated with adverse prognosis, while patients with biCEBPA mutations, RUNX1‐RUNXT1T1, and CBFβ‐MYH11 seem to have a relatively good outcome.10, 16, 17, 18, 19, 20, 21, 22 However, our knowledge concerning distribution and prognostic significance of gene alterations in e/s‐AML patients remains scarce. The gene discussed is FLT3; the disease is acute myeloid leukemia.